CD38 and Miyoshi myopathy: Despite the availability of proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and anti-CD38 antibodies, which have significantly improved the prognosis of MM patients in recent years, most still experience a pattern of alternating remissions and relapses [13,14], generally with progressively shorter durations of response to each subsequent regimen [15].